Perficient: Drug Development

AUGUST 24, 2023

Understanding GraphQL: At its core, GraphQL is a query language and runtime for APIs that was developed by Facebook in 2012 and later open-sourced in 2015. In this comprehensive exploration, we’ll dive deep into the essence of GraphQL, its core principles, benefits, and real-world applications.

Production 98

Production 98

Drug Target Review

AUGUST 9, 2024

The science behind drug formulation The formulation of a drug is both an art and a science, requiring a deep understanding of the drug’s chemical and physical properties. 1 Challenges in drug formulation Developing a successful drug formulation is fraught with challenges.

Science 59

Science Drugs Compliance Drug Development 59

Perficient: Drug Development

SEPTEMBER 11, 2023

When I joined Perficient in 2015, I was brand new to Sitecore. I wrote my Sitecore Bootcamp for Developer series for myself as well as for others that had been in my position of having to learn Sitecore from scratch. link] [link] [link] [link] Sitecore Most of my work at Perficient has been focused on the Sitecore platform.

Doctors 104

Doctors 104

Drug Target Review

JUNE 21, 2023

The druggable genome and support for target identification and validation in drug development. 2015 Sep 29;6:8382. 2015 Nov 19;163(5):1204-1213. Epub 2015 Nov 12. Sci Transl Med. 2017 Mar 29;9(383):eaag1166. Doi: 10.1126/scitranslmed.aag1166. PMID: 28356508; PMCID: PMC6321762. medRxiv; 2023. Nat Commun.

Disease 111

Disease Clinical Trials Therapies Science 111

Drug Target Review

APRIL 9, 2024

Initial works from the lab concentrated on exploring the role of replicative stress in cancer and ageing, for which the group combined cell biology, mouse models and drug development projects. Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy.

RNA 64

RNA Cell Biology Clinical Development Disease 64

Fierce BioTech

OCTOBER 26, 2023

Davis Duration 60 minutes The drug discovery process is risky, expensive, and notoriously cumbersome, with an average of 10+ years and hundreds of millions of dollars to develop and bring a drug to market.

Science 52

Science Drug Development Research Drugs 52

LifeSciVC

JULY 11, 2023

The meeting brings together tens of thousands of physicians, scientists, patients, advocates, innovators, and those involved in oncology drug development from around the world in order to explore the latest advances in cancer treatment, clinical trials, and translational and clinical research.

Therapies 66

Therapies Trials Clinical Development Science 66

NIH Director's Blog: Drug Development

SEPTEMBER 29, 2015

While these neural constructs appear to have a bright future in drug development, they also hold great promise for evaluating the neurotoxicity of non-pharmacologic chemicals and for understanding the processes associated with normal and abnormal brain development. 2015 Sep 21. Nat Biotechnol. 2014 Jan;32(1):40-51. [2]

RNA 52

RNA Science Laboratories Clinical Trials 52

Vial

MAY 13, 2024

Introduction The biopharma industry is poised to make revolutionary advances in and redefine drug development, and the current climate for innovation appears ideal. According to Rodríguez-Molinero et al., only 5% of molecules in oncology Phase I trials reach the market taking, on average, 7.5

Clinical Trials 52

Clinical Trials Trials Drug Development Production 52

Perficient: Drug Development

MAY 1, 2024

Subscribe Where You Listen Apple | Spotify | Amazon | Google | Stitcher Meet our Guest James Hannis, Chief Architect – Customer Engagement and Enterprise Solutions James Hannis, the chief architect at Cardinal Health since 2015, is a visionary IT executive known for his work in multi-channel retailing.

Marketing 52

Marketing Production 52

The Pharma Data

MARCH 15, 2022

To further facilitate generic drug development, and to assist the generic pharmaceutical industry in this process, the FDA publishes product-specific guidances (PSGs) describing the agency’s current thinking and expectations on how to develop generic drug products that are therapeutically equivalent to their brand name counterparts.

FDA Approval 52

FDA Approval FDA Production Drug Development 52

LifeSciVC

AUGUST 30, 2023

– “The Authenticity Paradox” Harvard Business Review, 2015 After an intense twelve months at Third Harmonic Bio, this blog post assignment snuck up on me. There’s no real hack in our industry – learning drug development is an apprenticeship process. wait for it, cringe). change in how we do what we do.

International 65

International FDA Drug Development Drugs 65

Vial

FEBRUARY 29, 2024

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies. Every year, thousands of clinical trials take place, and a large percentage of these are overseen by CROs.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

PLOS: DNA Science

SEPTEMBER 5, 2024

Targeted cancer drugs developed to treat one type of cancer often expand, with further testing, to treat other types, based on molecular similarities. Diagnosis began to shift from a body-part basis to a molecular one, which I wrote about in “Mutation and location important in cancer treatment” for The Lancet in 2015.

Treatment 71

Treatment FDA Approval DNA Small Molecule 71

Drug Target Review

OCTOBER 3, 2024

In 2024 alone, almost 50 antibody drug candidates are anticipated to enter regulatory review, the majority of which are mAbs. Aside from the advent of complex antibody-based drugs, the industry is facing some additional changes which are shaping drug development. 2015 May;521(7552):274–6. 2018;10(4):539–46.

Molecular Biology 52

Molecular Biology Pharmacokinetics Laboratories Animal Testing 52

New Drug Approvals

SEPTEMBER 13, 2024

4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 12] Positron emission tomography imaging revealed that brain KORs were almost completely saturated by the drug 2.5 18] In February 2015, Cerecor Inc.

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

The Pharma Data

AUGUST 21, 2020

Eli Lilly, on the heels of detailing a clinical win in China for PD-1 inhibitor Tyvyt, has decided to take a bigger stake in the drug developed by partner Innovent Biologics in an expanded deal that could vault it into the lucrative—yet ultra-competitive—U.S. Lilly first licensed Tyvyt from Innovent in 2015. lung cancer market.

Licensing 52

Licensing Licensing FDA Therapies 52

The Pharma Data

DECEMBER 13, 2020

Dr. Zhang has around 20 years of experience in research and drug development in both industry and academia in the US. Before that, he was Director of Development at Cobalt Biomedicine leading CAR-T and other cell/gene therapy programs, and R&D Director at OvaScience developing stem cell-based products.

Medical Schools 40

Medical Schools Clinical Development Therapies RNA 40

Dark Matter Blog

JUNE 21, 2023

As a small biotech company with new technology at the frontier of the known drug discovery universe, it may feel like you’re charting a course alone in a dark, cold, and empty void with hailing frequencies open, but with no incoming transmissions. But you would be wrong. This latter course is Arrakis’ strategy.

Small Molecule 52

Small Molecule RNA Pharma Companies Science 52

NIH Director's Blog: Drug Development

JULY 20, 2017

The next major milestone on the therapeutic pathway was the FDA’s approval in 2015 of Orkambi, a drug that combines ivacaftor with lumacaftor, the first “corrector”. That combination therapy was designed to help CF patients with two copies of the F508del mutation.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Disease 52

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.  Jaccard, E.,

Disease 98

Disease Treatment Drugs Clinical Trials 98

The Pharma Data

JANUARY 11, 2021

commented, “We believe that this investment will meaningfully accelerate MediciNova’s drug development in the pipeline and could lead to unleashing its highest potential in value. is a value-oriented investment manager founded in 2015 and based in Singapore. About 3D Investment Partners. 3D Investment Partners Pte.

Clinical Trials 52

Clinical Trials Trials Vaccine Small Molecule 52

The Pharma Data

OCTOBER 25, 2020

The platform harnesses electron-transfer chemistry to modulate key biological processes beyond the reach of current drug development approaches. 2015; Chevallier et al. About PTC Therapeutics, Inc. 1 Gorman et al. Annals of Neurology.2015; 2014; View original content: [link].

Clinical Trials 52

Clinical Trials Trials Small Molecule Regulations 52

The Pharma Data

DECEMBER 30, 2020

ImmVira was founded on May 18, 2015 as a biotechnology company focused on genetically modified oncolytic viruses (“OV”) as potential cancer therapeutics. For the company, the joining of highly experienced CMO and CFO would ensure our clinical and financing functions operate at the world class level.

Virus 40

Virus International Trials Clinical Trials 40

The Pharma Data

FEBRUARY 18, 2022

3 Globally, in 2015, there were approximately 30 million cases of acute lower respiratory infections leading to more than three million hospitalisations, and it was estimated that there were 60,000 in-hospital deaths of children younger than five years. 1-3 It is also a leading cause of hospitalisations in all infants.

Virus 40

Virus Trials Disease Clinical Trials 40

The Pharma Data

JUNE 25, 2021

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for AD.

Disease 40

Disease Treatment Therapies FDA 40

Perficient: Drug Development

MARCH 31, 2024

I remember myself back in 2015 creating a powerful UI wrapper for Selenium WebDriver to automate and simplify it operations for non-technical users. Selenium is aimed more at QA automation specialists, while Cypress is aimed merely at developers to improve TDD efficiency. Installation and first run You need to have Node.js

Engineering 52

Engineering 52

NIH Director's Blog: Drug Development

APRIL 7, 2015

2015 Feb 23. Nat Neurosci. 2012 Sep;15(9):1227-35. doi: 10.1038/nn.3178. 2] Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, Robinson SA, Gunther EC, van Dyck CH, Nygaard HB, Strittmatter SM. Ann Neurol.

Disease 40

Disease Drugs Clinical Trials Science 40

Perficient: Drug Development

JUNE 20, 2023

Back in the bygone times of 2015, 62% of American smartphone owners reported using their mobile devices to search for health information. This simple step turns your phone numbers into HTML links that a website user can click or tap within your page, instantly connecting them to your contact center, office staff members or other team members.

Marketing 52

Marketing 52

The Pharma Data

SEPTEMBER 8, 2021

executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world.

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

JULY 29, 2021

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for AD.

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

JANUARY 12, 2021

Massive Bio is an AI-driven platform connecting cancer patients and their oncologists to bio-pharmaceutical clinical trials, yielding profound improvement in access and match rates, leading to faster drug development timelines, and creating a novel oncology data ecosystem for improved protocol design and real-world insights.

Clinical Trials 52

Clinical Trials Trials Clinical Research Pharmaceutical Companies 52

Perficient: Drug Development

JULY 10, 2023

Expected Output Initially Vivek was in Gurgaon office but moved to California after 10 Jan 2015. Below is an example where we have source system as source while data warehouse table as our target which maintains history. Dynamic Merge for SCD Type 2 Source – EMP_STG Table looks like below.

52

52

The Pharma Data

APRIL 25, 2021

In Japan, nirsevimab was also selected by the Japan Agency for Medical Research and Development (AMED) as “a medicine for prioritized development” under the Project for Drug Selection to Promote New Drug Development in Pediatrics. . About Sanofi. . Lancet 2017; 390: 946–58. Rha B et al. Pediatrics. Leader S.,

Virus 40

Virus Trials Disease Hospitals 40

Perficient: Drug Development

OCTOBER 12, 2023

In 2015, GraphQL was made open source, and Airbnb, GitHub, Pinterest, Shopify, and many other companies now use GraphQL. When Facebook developers created a mobile application, they looked for ways to speed things up.

Production 69

Production 69

Agency IQ

JUNE 29, 2023

To implement that authority, FDA published a final rule in the Federal Register on September 15, 2015 [80 FR 55237] which revised 21 CFR 1.94 to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. .;

FDA 40

FDA Science Regulations Production 40

Agency IQ

OCTOBER 6, 2023

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), “between 2008 and 2015, amphetamine-related hospitalizations more than tripled, increasing from 55,447 instances to 206,180. Regulatory context FDA held a workshop in December 2019 to discuss development of substance use disorder therapies.

FDA 40

FDA Treatment Production Trials 40